Protective efficacy of the Chinese vaccine BBIBP-CorV (Sinopharm) – 86%
The COVID-19 vaccine regiment, for which there is already preliminary data on protective efficacy, has arrived. The OAE Ministry of Health announced that an interim analysis of the results of a Phase 3 clinical trial of Sinopharm’s BBIBP-CorV Chinese vaccine showed an 86% protective efficacy against COVID-19. At the same time, permission was given for the widespread use of this vaccine in the OAE (before that its use in the OAE was allowed only for the vaccination of medical personnel).
No details yet. The developer of this vaccine is the Beijing Institute of Biological Products. Clinical trials of the vaccine are carried out in the OAE, Bahrain, Jordan, Morocco, Peru, Argentina. Trials at the OAE (Phase 3) began in July 2020 and are involving 31,000 people. Vaccine BBIBP-CorV Inactivated-Whole Virus. Read more about this platform here: https://prof-afv.livejournal.com/52533.html. The immunization course consists of two injections with an interval of 3 weeks. The storage conditions for this vaccine are a regular refrigerator (+ 4 / + 8 degrees C). Sinopharm President said that China has already immunized about a million people with this vaccine. In this case, he said, no serious adverse reactions were found.
Sinopharm has a very large production capacity for the production of inactivated whole-virus vaccines. In addition to BBIBP-CorV, Sinopharm’s portfolio includes another inactivated whole-virus vaccine against COVID-19, developed by the Wuhan Institute of Biological Products. This vaccine is also being tested in the UAE and several other countries. In the UAE, its use is already allowed among medical personnel. Hopefully, more detailed scientific information will not be long in coming.